1. Home
  2. OR vs RGEN Comparison

OR vs RGEN Comparison

Compare OR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OR
  • RGEN
  • Stock Information
  • Founded
  • OR 2014
  • RGEN 1981
  • Country
  • OR Canada
  • RGEN United States
  • Employees
  • OR N/A
  • RGEN N/A
  • Industry
  • OR Precious Metals
  • RGEN Medical/Dental Instruments
  • Sector
  • OR Basic Materials
  • RGEN Health Care
  • Exchange
  • OR Nasdaq
  • RGEN Nasdaq
  • Market Cap
  • OR 7.4B
  • RGEN 6.5B
  • IPO Year
  • OR N/A
  • RGEN N/A
  • Fundamental
  • Price
  • OR $33.15
  • RGEN $166.77
  • Analyst Decision
  • OR Hold
  • RGEN Buy
  • Analyst Count
  • OR 4
  • RGEN 11
  • Target Price
  • OR $36.25
  • RGEN $167.90
  • AVG Volume (30 Days)
  • OR 1.4M
  • RGEN 1.1M
  • Earning Date
  • OR 11-05-2025
  • RGEN 10-28-2025
  • Dividend Yield
  • OR 0.60%
  • RGEN N/A
  • EPS Growth
  • OR N/A
  • RGEN N/A
  • EPS
  • OR 0.42
  • RGEN N/A
  • Revenue
  • OR $213,999,000.00
  • RGEN $673,956,000.00
  • Revenue This Year
  • OR $80.79
  • RGEN $16.77
  • Revenue Next Year
  • OR $12.96
  • RGEN $13.79
  • P/E Ratio
  • OR $79.55
  • RGEN N/A
  • Revenue Growth
  • OR 13.88
  • RGEN 8.73
  • 52 Week Low
  • OR $17.55
  • RGEN $102.97
  • 52 Week High
  • OR $42.25
  • RGEN $182.52
  • Technical
  • Relative Strength Index (RSI)
  • OR 36.33
  • RGEN 75.11
  • Support Level
  • OR $33.07
  • RGEN $155.74
  • Resistance Level
  • OR $35.18
  • RGEN $165.11
  • Average True Range (ATR)
  • OR 1.53
  • RGEN 5.73
  • MACD
  • OR -0.95
  • RGEN 1.06
  • Stochastic Oscillator
  • OR 2.10
  • RGEN 88.26

About OR Osisko Gold Royalties Ltd

OR Royalties Inc, formerly Osisko Gold Royalties Ltd is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: